Objective:To perform a systematic review and meta-analysis on the efficacy and safety of Tanreqing Injection in trea-ting chronic obstructive pulmonary disease(COPD)combined with respiratory failure.Methods:China National Knowledge Infra-structure,China Biology Medicine,China Science Periodical Database,Chinese Citation Database,PubMed,Cochrane Library,Web of Science,and Embase were searched for the randomized controlled trials(RCTs)of Tanreqing Injection in the treatment of COPD combined with respiratory failure.RevMan 5.4 was used for the systematic review and meta-analysis of the included studies,and the Grading of Recommendations Assessment,Development and Evaluation(GRADE)system was used to estimate the quality of out-come indicators.Results:Thirteen clinical studies were included in this study,involving a total of 1 007 patients(505 in the obser-vation group and 502 in the control group).In the treatment of COPD patients with respiratory failure,Tanreqing Injection combined with conventional Western medicine showed significant differences compared with the control group in terms of the total response rate(OR=3.52,95％CI 2.35 to 5.27,P＜0.000 01),arterial pH(MD=0.04,95％CI 0.02 to 0.05,P＜0.000 01),arterial par-tial pressure of oxygen(MD=7.86,95％CI 7.24 to 8.48,P＜0.000 01),arterial partial pressure of carbon dioxide(MD=-6.85,95％CI-8.99 to-4.77,P＜0.000 01),and tumor necrosis factor-α(TNF-α)(SMD=-2.56,95％CI-4.11 to-1.01,P＜0.01).GRADE evidence indicated that the total response rate,arterial pH,arterial partial pressure of oxygen,and arte-rial partial pressure of carbon dioxide were low-quality evidence,and TNF-α was the evidence of extremely low quality.Conclu-sion:Conventional Western medicine combined with Tanreqing Injection improves the total response rate,reduces hypoxemia or/and carbon dioxide retention,and alleviates inflammation in the treatment of COPD combined with respiratory failure,with good safety,being worthy of promotion and application.
维普
万方数据